Hansa Biopharma announces positive Idefirix PAES results presented in the High-Impact Clinical Trials session at ASN Kidney Week

Impact · against what's priced in

Hansa Biopharma's positive PAES study results provide the necessary clinical evidence to transition Idefirix from conditional to full marketing authorization in Europe. This reduces regulatory risk and supports the commercial expansion of the drug for highly sensitized kidney transplant patients.

HNSA+0.60: No priced-in read yet

Hansa Biopharma announces positive Idefirix PAES results presented in the High-Impact Clinical Trials session at ASN Kidney Week

What matters in this story

Ondine Biomedical says Canadian hospital findings reinforces Steriwave's point of care value

Hansa Biopharma announces positive Idefirix PAES results presented in the High-Impact Clinical Trials session at ASN Kidney Week

What matters in this story

Ondine Biomedical says Canadian hospital findings reinforces Steriwave's point of care value

How each ticker is affected

Track these names every morning.

GH Research Remains Undervalued Ahead Of Pivotal Phase III Program

Korro Bio, Inc. (KRRO) Surges 29.7%: Is This an Indication of Further Gains?

U.S. Treasury Wants to Rein In Deals for Chinese Biotech and AI

Medpace: 3 Key Takeaways for Long-Term Investors

Hansa Biopharma announces positive Idefirix PAES results presented in the High-Impact Clinical Trials session at ASN Kidney Week

What matters in this story

Next reads from the same story arc

Ondine Biomedical says Canadian hospital findings reinforces Steriwave's point of care value

Hansa Biopharma announces positive Idefirix PAES results presented in the High-Impact Clinical Trials session at ASN Kidney Week

What matters in this story

Next reads from the same story arc

Ondine Biomedical says Canadian hospital findings reinforces Steriwave's point of care value

How each ticker is affected

Track these names every morning.

GH Research Remains Undervalued Ahead Of Pivotal Phase III Program

Korro Bio, Inc. (KRRO) Surges 29.7%: Is This an Indication of Further Gains?

U.S. Treasury Wants to Rein In Deals for Chinese Biotech and AI

Medpace: 3 Key Takeaways for Long-Term Investors